Clinical trials: Etoposide, completed
Brain and Central Nervous System Tumors
Etoposide Plus Cisplatin in Treating Patients With Recurrent Ependymomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002876
- Testing
- cisplatin, etoposide
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Mayo Clinic
Extragonadal Germ Cell Tumor, Ovarian Cancer
Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002489
- Testing
- dactinomycin, filgrastim, carboplatin
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Alveolar Childhood Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma
Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma
Randomized phase II trial to compare the effectiveness of different combination chemotherapy regimens in treating children who have rhabdomyosarcoma.
- Conditions
- Alveolar Childhood Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Previously Treated Childhood Rhabdomyosarcoma
- Trial name
- NCT00025363
- Testing
- vincristine sulfate, irinotecan hydrochloride, cyclophosphamide
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung, Synchronous Neoplasms
Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma
Non-small cell lung cancer (NSCLC) is the most frequent neoplasm worldwide and also represents the main cause of cancer death. However, it represents the main cause of death by cancer.
- Trial name
- NCT02805530
- Testing
- First line systemic treatment, Radical treatment, radiation therapy
- Where
- Mexico
- Volunteers
- 36 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Lymphoma
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous peripheral stem cell transplantation may allow the doctor to give…
- Trial name
- NCT00003957
- Testing
- filgrastim, recombinant human stem cell factor, cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Fox Chase Cancer Center
Ovarian Cancer, Sarcoma
Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Ovarian Cancer, Sarcoma, Small Intestine Cancer
- Trial name
- NCT00025441
- Testing
- dactinomycin, filgrastim, carboplatin
- Where
- 22 sites in France, Ireland and 1 more
- Sponsor
- Societe Internationale d'Oncologie Pediatrique
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
This phase I/II trial studies the side effects and best dose of brentuximab vedotin that can be combined with ifosfamide, carboplatin, and etoposide in treating patients with Hodgkin lymphoma that has come back (relapsed) or is…
- Trial name
- BV-ICE (NCT02227199)
- Testing
- Brentuximab Vedotin, Carboplatin, Etoposide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Washington
Lymphoma
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
The goal of this clinical research study is to compare chemotherapy given with rituximab to chemotherapy followed by rituximab. The safety of both treatment schedules will be studied.
- Trial name
- NCT00577993
- Testing
- Fludarabine, Novantrone, Decadron
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- M.D. Anderson Cancer Center
Tumors, Solid Malignant Tumors
Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
This is a phase 1/2 study evaluating safety, tolerability, and efficacy of lenvatinib as single-agent, and in combination with chemotherapy (ifosfamide and etoposide) in children and adolescents with refractory or relapsed solid…
- Conditions
- Tumors, Solid Malignant Tumors, Osteosarcoma, Differentiated Thyroid Cancer (DTC)
- Trial name
- NCT02432274
- Testing
- Lenvatinib, Ifosfamide, Etoposide
- Where
- 19 sites in United States, France and 4 more
- Volunteers
- 117 people
- Sponsor
- Eisai Limited
Lung Cancer, Chemotherapy Effect
The Effect of Immersive Virtual Reality and Relaxing Videos on Lung Cancer Patients
Lung cancer is one of the types of cancer with a high incidence and mortality rate in the world and in our country. Frequently used protocols in the chemotherapy treatment of lung cancer are the Platinum-based drugs.
- Conditions
- Lung Cancer, Chemotherapy Effect, Distress, Emotional, Quality of Life (QOL)
- Trial name
- NCT06863623
- Testing
- Immersive Virtual Reality, Relaxing Videos
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 315 people
- Sponsor
- Hacettepe University
Non Small Cell Lung Cancer
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
This study will compare the overall survival of participants with locally-advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) with nonsquamous cell histology.
- Trial name
- PROCLAIM (NCT00686959)
- Testing
- Pemetrexed, Cisplatin, Etoposide
- Where
- 133 sites in United States, Argentina and 17 more
- Volunteers
- 598 people
- Sponsor
- Eli Lilly and Company
Sarcoma, Soft Tissue
Neoadjuvant Adriamycin and Ifosfamide Plus High-Dose ICE in Patients With Soft Tissue Sarcoma (STS)
Complete resection is still the only curative treatment option in patients with soft tissue sarcoma (STS). Patients with a non-resectable STS have a dismal prognosis even without evidence of metastatic disease.
- Trial name
- NCT00204646
- Testing
- Adriamycin, Ifosfamide, Etoposide
- Where
- Germany
- Sponsor
- University Hospital Tuebingen
Lymphoma, Hodgkin Disease, Lymphoma
Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Lymphoma, Hodgkin Disease, Lymphoma, Hodgkin Disease, Lymphoma: Hodgkin
- Trial name
- NCT00026208
- Testing
- Vincristine, Cyclophosphamide, Doxorubicin
- Where
- 2 sites in United States
- Volunteers
- 76 people
- Sponsor
- Stanford University
Non-Squamous Non-Small Cell Lung Cancer
A Study of Avastin (Bevacizumab) in Combination With Thoracic Radiation and Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.
This single arm study will evaluate the feasibility of treatment with 2 dose levels of Avastin in combination with concurrent thoracic radiation and chemotherapy in patients with locally advanced unresectable non-squamous…
- Trial name
- NCT00776698
- Testing
- bevacizumab [Avastin], cisplatin, etoposide
- Where
- 5 sites in Netherlands, United Kingdom
- Volunteers
- 1 people
- Sponsor
- Hoffmann-La Roche
Leukemia, Myelocytic, Acute
Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
The purpose of this study is to compare the effectiveness of two multi-agent chemotherapy regimens using different dosages of cytarabine to eliminate all detectable leukemia.
- Trial name
- NCT00136084
- Testing
- Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine
- Where
- 8 sites in United States
- Volunteers
- 238 people
- Sponsor
- St. Jude Children's Research Hospital
Osteosarcoma
A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma
This Is a Multicenter, Randomized, Open-Label, Parallel-Group, Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide Versus Ifosfamide and Etoposide in Children, Adolescents…
- Trial name
- NCT04154189
- Testing
- Lenvatinib, Ifosfamide, Etoposide
- Where
- 84 sites in United States, Australia and 19 more
- Volunteers
- 81 people
- Sponsor
- Eisai Inc.
Diffuse Large Cell Lymphoma, Burkitt's Lymphoma
Treatment for Advanced B-Cell Lymphoma
To safely reduce the burden of therapy in children, adolescents and young adults with mature B-NHL by reducing the number of intrathecal (IT) injections by the introduction of IT Liposomal Cytarabine (L-ARA-C, [Depocyt®]) and…
- Conditions
- Diffuse Large Cell Lymphoma, Burkitt's Lymphoma, High Grade B-cell Lymphoma
- Trial name
- REBOOT (NCT01859819)
- Testing
- Rituximab, IT Cytarabine
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- New York Medical College
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma
Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
This phase I/II trial is studying the side effects and best dose of oblimersen when given together with rituximab and combination chemotherapy and to see how well they work in treating patients with relapsed or refractory…
- Conditions
- Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma
- Trial name
- NCT00086944
- Testing
- oblimersen sodium, rituximab, ifosfamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Radiation Therapy Plus Combination Chemotherapy In Treating Patients With Limited Stage Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003364
- Testing
- cisplatin, cyclophosphamide, doxorubicin hydrochloride
- Where
- 14 sites in United Kingdom
- Volunteers
- 398 people
- Sponsor
- London Lung Cancer Group
Bladder Cancer, Brain and Central Nervous System Tumors
High-dose ICE With Amifostine
The purpose of the study is to evaluate the combination of amifostine and high dose chemotherapy with blood stem cell support. Amifostine is a druf developed to protect normal tissues against the toxicities of chemotherapy and…
- Conditions
- Bladder Cancer, Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Extragonadal Germ Cell Tumor
- Trial name
- NCT00003657
- Testing
- filgrastim, Amifostine, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Dana-Farber Cancer Institute